Published in JAMA on March 16, 2011
Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response (OPTIMAL) | NCT01955200
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J (2015) 1.29
Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23
Practical challenges in integrating genomic data into the electronic health record. Genet Med (2013) 1.14
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis (2012) 0.97
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. PLoS One (2014) 0.95
Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J (2015) 0.95
Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol (2011) 0.92
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Charting a roadmap for heart failure biomarker studies. JACC Heart Fail (2014) 0.90
Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol (2015) 0.89
Stent thrombosis: incidence, predictors and new technologies. Thrombosis (2012) 0.87
Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther (2016) 0.87
Clopidogrel Resistance by P2Y12 Platelet Function Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ischemic and Hemorrhagic Complications. J Vasc Interv Neurol (2013) 0.86
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej (2015) 0.84
The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol (2011) 0.84
Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting. Korean Circ J (2013) 0.84
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J (2012) 0.83
Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group. JACC Basic Transl Sci (2016) 0.83
Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials. Int J Clin Exp Med (2015) 0.83
High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging (2012) 0.83
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet (2013) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One (2015) 0.82
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J (2014) 0.82
Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol (2015) 0.82
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open (2014) 0.81
The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline: a critical appraisal. Methodist Debakey Cardiovasc J (2012) 0.81
Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract (2012) 0.81
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol (2014) 0.80
A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. Clin Res Cardiol (2014) 0.80
Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Ther Clin Risk Manag (2015) 0.80
Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Br J Clin Pharmacol (2012) 0.80
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA (2011) 0.80
Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. Thromb Res (2014) 0.80
Personalized vascular medicine: individualizing drug therapy. Vasc Med (2011) 0.79
Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart (2014) 0.79
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World J Cardiol (2015) 0.79
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Eur J Clin Pharmacol (2015) 0.78
The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis. Biomed Res Int (2014) 0.78
Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol (2013) 0.78
Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78
Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor. Clin Pharmacol (2013) 0.78
Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of function polymorphisms (*2/*3). Int J Cardiol (2016) 0.78
Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study. Yonsei Med J (2012) 0.77
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J (2015) 0.77
Pharmacogenomic testing and antithrombotic therapy: ready for prime time? Rambam Maimonides Med J (2013) 0.77
High-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One (2013) 0.77
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep (2015) 0.77
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wien Klin Wochenschr (2011) 0.77
Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry. PLoS One (2014) 0.76
P2Y12 platelet receptors: importance in percutaneous coronary intervention. Arq Bras Cardiol (2013) 0.76
Standard- vs high-dose clopidogrel after percutaneous coronary intervention. JAMA (2011) 0.76
Phenotyping patient-derived cells for translational studies in cardiovascular disease. Circulation (2011) 0.76
Should platelet function testing guide antiplatelet therapy for patients with coronary artery stenting or acute coronary syndromes? Clin Chem (2013) 0.76
Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs. Ther Adv Drug Saf (2015) 0.75
Acute coronary syndromes in 2016: Assessing strategies to improve patient management. Nat Rev Cardiol (2017) 0.75
Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol (2012) 0.75
Standard- vs high-dose clopidogrel after percutaneous coronary intervention. JAMA (2011) 0.75
The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count. PLoS One (2016) 0.75
Type 2 Diabetes and ADP Receptor Blocker Therapy. J Diabetes Res (2015) 0.75
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol (2013) 0.75
Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome. Korean Circ J (2012) 0.75
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. Med Sci Monit (2015) 0.75
Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping. J Am Heart Assoc (2013) 0.75
Successful prasugrel rescue therapy in clopidogrel resistant patients who had recurrent stent thrombosis of drug-eluting-stent: the role of prasugrel in clopidogrel nonresponders. Korean Circ J (2013) 0.75
ARCTIC: Additional proof against antiplatelet adjusted therapy. Glob Cardiol Sci Pract (2013) 0.75
The P2Y(12) receptor as a target of antithrombotic drugs. Purinergic Signal (2011) 0.75
Neurointerventional Stenting and Antiplatelet Function Testing: To Do or Not to Do? Interv Neurol (2015) 0.75
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol (2011) 0.75
Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Mater Sociomed (2011) 0.75
Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. BMJ Open (2014) 0.75
Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting. Genomics (2013) 0.75
Genes and Cardiovascular Disease: Where do we go from here? Sultan Qaboos Univ Med J (2015) 0.75
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients. Braz J Med Biol Res (2017) 0.75
The CYP2C19(∗)1/(∗)2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers. Cardiol Res Pract (2013) 0.75
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. PLoS One (2015) 0.75
Personalized antiplatelet therapy: state of the art. JRSM Cardiovasc Dis (2012) 0.75
A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome. Korean J Intern Med (2015) 0.75
Towards personalized medicine based on platelet function testing for stent thrombosis patients. Thrombosis (2012) 0.75
Platelet Function Testing-Guided Antiplatelet Therapy. EJIFCC (2013) 0.75
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. J Thromb Thrombolysis (2014) 0.75
PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. BMC Med Genet (2017) 0.75
Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol (2017) 0.75
Blood-Derived Extracellular RNA and Platelet Pathobiology: Adding Pieces to a Complex Circulating Puzzle. Circ Res (2016) 0.75
Routine genotyping of patients on clopidogrel: Why the resistance? Indian Heart J (2015) 0.75
Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study. J Geriatr Cardiol (2015) 0.75
Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. Am J Cardiovasc Dis (2011) 0.75
A Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI]. PLoS One (2015) 0.75
Controversies in the use & implementation of drug-eluting stent technology. Indian J Med Res (2012) 0.75
Clopidogrel resistance - a clear problem with an unclear solution. Indian Heart J (2012) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Statistical analysis strategies for association studies involving rare variants. Nat Rev Genet (2010) 6.79
Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys (2006) 6.51
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med (2012) 6.27
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Comparative effectiveness of revascularization strategies. N Engl J Med (2012) 5.49
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) (2012) 5.22
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol (2008) 5.19
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80
Can mobile health technologies transform health care? JAMA (2013) 4.75
The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell (2002) 4.72
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet (2004) 4.51
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Generalized born model with a simple smoothing function. J Comput Chem (2003) 4.36
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (2005) 4.21
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Accommodating linkage disequilibrium in genetic-association analyses via ridge regression. Am J Hum Genet (2008) 3.86
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J (2008) 3.84
Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J Comput Chem (2004) 3.83
Generalized genomic distance-based regression methodology for multilocus association analysis. Am J Hum Genet (2006) 3.79
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Transgenerational epigenetic instability is a source of novel methylation variants. Science (2011) 3.66
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv (2010) 3.24
Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv (2005) 3.20
Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol (2005) 3.20
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol (2005) 3.17
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16